<DOC>
	<DOCNO>NCT01592045</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( blood level ) safety chimeric ( ch ) 14.18 manufacture two independent drug maker ( United Therapeutics [ UTC ] National Cancer Institute [ NCI ] ) .</brief_summary>
	<brief_title>ch14.18 Pharmacokinetic Study High-risk Neuroblastoma</brief_title>
	<detailed_description>This multi-center , randomize , open-label , two-sequence , cross-over study eligible subject high-risk neuroblastoma ass comparability ch14.18 manufacture UTC drug product ch14.18 manufacture NCI drug product . Subjects randomly allocate receive ch14.18 manufacture UTC NCI Courses 1 2 follow ch14.18 manufacture manufacturer ( UTC NCI ) Courses 3 , 4 , 5 .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis highrisk neuroblastoma 8 year age young diagnosis highrisk neuroblastoma Patients must complete therapy include intensive induction follow autologous stem cell transplantation ( ASCT ) radiotherapy * Radiotherapy may waive patient either small adrenal mass completely resect front , never identifiable primary tumor Must meet International Neuroblastoma Response Criteria ( INRC ) CR , VGPR , PR primary site , soft tissue metastasis , bone metastasis AND must also meet protocol specify criterion bone marrow response follow : * No 10 % tumor ( total nucleate cellular content ) see specimen bilateral bone marrow aspirate/biopsy Patient tumor see prior bone marrow , â‰¤ 10 % tumor bilateral marrow aspirate/biopsy specimens do preASCT and/or preenrollment evaluation also eligible No 12 month start first induction chemotherapy diagnosis date ASCT * For patient become highrisk neuroblastoma initial nonhigh risk disease , 12 month period start date induction therapy highrisk neuroblastoma date ASCT No progressive disease time registration except protocolspecified bone marrow response Adequate hematological , renal , hepatic , pulmonary cardiac function CNS toxicity &lt; Grade 2 Prior antiGD2 antibody therapy Prior vaccine therapy neuroblastoma Concurrent anticancer immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>